Proteins with a high immunoreactivity and a method for the production thereof
AssigneeScintec Diagnostics GmbH
InventorsIvan Benes, Silke Thomsen-Bosslet
Life of this patent
Estimating the term…
Abstract
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labelled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha - or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labelled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.
Claims27
Preparation of immunoreactive proteins, characterized in that the percentage of immunoreactive molecules as determined in a modified Lindmo-test is >81% relative to the total number of molecules.
Method for preparing a preparation of immunoreactive proteins characterized in that it comprises a fluidized reactor fermentation of a host cell which expresses the immunoreactive protein in a suitable culture medium, and the recovering of the protein from the host cell and/or from the culture medium.
Dependencies are inferred from the claim text.